Alpine Immune Sciences

Modern therapies targeting the immune synapse


Alpine Immune Sciences

Novel proteins created using directed evolution-based discovery platform


Alpine Immune Sciences

Helping patients with cancer and autoimmune disease


Modern therapies targeting the immune synapse

We create protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases.

Alpine Immune Sciences capitalizes on our unique understanding of the immune synapse, using our directed evolution platform to engineer native immune system proteins for therapeutic benefit.

Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model

— ALPN-202 is a potential novel immuno-oncology therapy providing dual
PD-L1/CTLA-4 antagonism with CD28 costimulation —

— Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies —

 — Data Presented at 2018 American Association for Cancer Research Annual Meeting —

Read More

At Alpine Immune Sciences, we are applying our platform discovery technology to bring innovative new drugs to people living with cancer and autoimmune/inflammatory diseases

Directed Evolution Platform

Alpine’s powerful directed evolution platform is based upon proteins native to the immune synapse, engineering potentially novel “Variant immunoglobulin domains” or “vIgDs”. Our vIgDs can engage multiple targets simultaneously, can be significantly more potent then native proteins, and have the potential improve therapeutic outcomes for the treatment of cancer, autoimmune/inflammatory conditions, or infectious diseases.

Because vIgDs are based upon natural participants in the immune synapse, they potentially provide a mechanistic advantage over larger, more artificial constructs.

Lead Programs

ALPN-101 is a dual ICOS/CD28 antagonist being developed for the treatment of autoimmune and inflammatory diseases. We plan to request regulatory approval to begin clinical trials of ALPN-101 Q4-2018.

ALPN-202 is a multi-action PD-L1/CTLA-4 inhibitor and CD28 costimulator being developed for the treatment of cancer. We plan to request regulatory approval to begin clinical trials of ALPN-202 in 2019.

Our Transmembrane Immunomodulatory Protein (TIP) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL. TIPs are based upon our core vIgD technology, but are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.